June 6, 2012 9:27 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S.Food and Drug Administration for its abbreviated new drug application (ANDA)for calcium acetate capsules, the generic equivalent of Phoslo(R) Gelcaps.Perrigo was previously in patent litigation over this product with the brandand the litigation settled in late 2011. The terms of the settlement areconfidential. Gelcaps annual brand and equivalent generics sales were approximately $95million, as measured by Wolters Kluwer Health. Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This productis another example of Perrigo's commitment to expand our portfolio and bringnew products to market. This is another demonstration of our strategy toprovide more affordable, high quality healthcare products to patients." Perrigo Company is a leading global healthcare supplier that develops,manufactures and distributes OTC and generic prescription (Rx)
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.